Skye Bioscience to Showcase Nimacimab Data at Keystone Obesity Conference
Event summary
- Skye Bioscience will present a poster at the Keystone Obesity Conference on January 28, 2026.
- The poster will discuss the efficacy of nimacimab, a peripherally-restricted CB1-inhibitor antibody, in combination with tirzepatide and as a maintenance therapy.
- Nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects.
- Skye is conducting a Phase 2a clinical trial for nimacimab in obesity, assessing its combination with a GLP-1R agonist (Wegovy).
The big picture
Skye Bioscience's presentation at the Keystone Obesity Conference highlights the growing interest in combination therapies for obesity. The company's focus on peripherally-restricted CB1 inhibitors positions it in a competitive landscape where additive effects with existing treatments like GLP-1 agonists could be a key differentiator. The Phase 2a trial results will be critical in determining nimacimab's potential as a maintenance therapy post tirzepatide discontinuation.
What we're watching
- Clinical Efficacy
- How nimacimab's additive effects with incretin agonists will impact its market potential.
- Regulatory Pathway
- Whether the Phase 2a trial results will support further clinical development and regulatory approval.
- Competitive Positioning
- The pace at which Skye can differentiate nimacimab in the crowded obesity treatment market.
Related topics